Taking people in United StatesPhase 2/3

Testing a New Eye Injection Against Aflibercept for Wet Macular Degeneration

Compares tiespectus with aflibercept in people with neovascular age-related macular degeneration.

Plain-language title generated from the registry record
Registry title: A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Key facts

Where: Abilene, Aiken, Albuquerque, Altamonte Springs, Amarillo, Arlington, Austin, Bellaire, Bethlehem, Bluffton, Burlington, Carmel, Charleston, Cherry Hill, Cincinnati, Dallas, Edmond, Fayetteville, Fort Lauderdale, Gainesville, Germantown, Glendale, Grand Rapids, Greensboro, Greenville, Hagerstown, Hattiesburg, Hauppauge, Jacksonville, Lakeland, Liverpool, Lynchburg, Madison, Miami, Modesto, Mt. Pleasant, Oak Park, Palm Beach Gardens, Pasadena, Plano, Plantation, Portland, Redlands, Sacramento, Saint Louis Park, Salt Lake City, Scottsdale, Southlake, Spokane, Springdale, Springfield, St. Petersburg, Tallahassee, Tampa, The Woodlands, Tulsa, Tyler, Wausau, Weatherford, Wildwood, and Winston-Salem, United StatesSee the 67 sites
Phase: Phase 2/3

Where in United States

Retina Research Institute of Texas (Site 010)Abilene, United StatesTaking people
Palmetto Retina CenterAiken, United StatesTaking people
Vision Research Center Eye Associates of New MexicoAlbuquerque, United StatesTaking people
Florida Eye Clinic (Site 130)Altamonte Springs, United StatesTaking people
Southwest Retina SpecialistsAmarillo, United StatesTaking people
Texas Retina AssociatesArlington, United StatesTaking people
Austin Research Center for RetinaAustin, United StatesTaking people
Austin Retina Associates (Site 012)Austin, United StatesTaking people
Retina & Vitreous of TexasBellaire, United StatesTaking people
Mid Atlantic Retina (Site 050)Bethlehem, United StatesTaking people
Charleston Neuroscience Institute - Bluffton (Site 124)Bluffton, United StatesTaking people
Pacific Northwest Retina (Site 112)Burlington, United StatesTaking people
Associated Vitreoretinal and Uveitis ConsultantsCarmel, United StatesTaking people
Midwest Eye InstituteCarmel, United StatesTaking people
Charleston Neuroscience Institute (Site 104)Charleston, United StatesTaking people
Retina Consultants, PLLCCharleston, United StatesTaking people
Mid Atlantic RetinaCherry Hill, United StatesTaking people
Cincinnati Eye Institute (Site 133)Cincinnati, United StatesTaking people
Texas Retina AssociatesDallas, United StatesTaking people
Retina Vitreous CenterEdmond, United StatesTaking people
Retina Center of ArkansasFayetteville, United StatesTaking people
Retina Group of Florida (Site 070)Fort Lauderdale, United StatesTaking people
Vitreo Retinal AssociatesGainesville, United StatesTaking people
Charles Retina InstituteGermantown, United StatesTaking people
Global Research Management, IncGlendale, United StatesTaking people
Foundation for Vision Research (Site 073)Grand Rapids, United StatesTaking people
Piedmont Retina Specialists - GreensboroGreensboro, United StatesTaking people
North Carolina Retina AssociatesGreenville, United StatesTaking people
Cumberland Valley Retina Consultants (Site 007)Hagerstown, United StatesTaking people
Retina Specialists of MississippiHattiesburg, United StatesTaking people
ong Island Vitreoretinal Consultants / Vitreoretinal Consultants of NY (Site 105)Hauppauge, United StatesTaking people
Florida Retina InstituteJacksonville, United StatesTaking people
Florida Retina ConsultantsLakeland, United StatesTaking people
Retina Vitreous Surgeons of CNY, PC (Site 033)Liverpool, United StatesTaking people
Piedmont Eye Center (Site 054)Lynchburg, United StatesTaking people
Mississippi Retina Associates (Site 084)Madison, United StatesTaking people
South Florida Retina InstituteMiami, United StatesTaking people
Retinal Consultants Medical Group (Site 024)Modesto, United StatesTaking people
Charleston Neuroscience Institute (CNI) d/b/a Retina Consultants of South CarolinaMt. Pleasant, United StatesTaking people
Illinois Retina AssociatesOak Park, United StatesTaking people
Retina Care SpecialistsPalm Beach Gardens, United StatesTaking people
Azul Vision / California Eye Specialists Medical Group, Inc.Pasadena, United StatesTaking people
Texas Retina (Site 037)Plano, United StatesTaking people
Fort Lauderdale Eye Institute (Site 042)Plantation, United StatesTaking people
EyeHealth NorthwestPortland, United StatesTaking people
Retina Northwest, PCPortland, United StatesTaking people
Retina Consultants of Southern California (Site 043)Redlands, United StatesTaking people
Retinal Consultants Medical Group (Site 020)Sacramento, United StatesTaking people
Retinal Consultants Medical Group (Site 022)Sacramento, United StatesTaking people
Retina Consultants of MinnesotaSaint Louis Park, United StatesTaking people
Retina Associates of UtahSalt Lake City, United StatesTaking people
Research Network Arizona / Retina Macula Institute of ArizonaScottsdale, United StatesTaking people
Retina Center of TexasSouthlake, United StatesTaking people
Spokane Eye Clinical Research (Site 075)Spokane, United StatesTaking people
Retina Partners of Northwest Arkansas, PLLCSpringdale, United StatesTaking people
Springfield ClinicSpringfield, United StatesTaking people
Retina Vitreous Associates of Florida (Site 049)St. Petersburg, United StatesTaking people
Southern Vitreoretinal AssociatesTallahassee, United StatesTaking people
Retina Associates of Florida, LLCTampa, United StatesTaking people
Retina Vitreous Associates of FloridaTampa, United StatesTaking people
Retina Consultants of Texas (Site 014)The Woodlands, United StatesTaking people
Tulsa Retina ConsultantsTulsa, United StatesTaking people
Tyler Retina Research InstituteTyler, United StatesTaking people
Eye Clinic of WisconsinWausau, United StatesTaking people
Strategic Clinical Research GroupWeatherford, United StatesTaking people
Wildwood Clinical Research / Florida Retina InstituteWildwood, United StatesTaking people
Piedmont Retina Specialists - Winston-SalemWinston-Salem, United StatesTaking people

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Print a page for my doctor

Trial details

Who runs it: EyeBiotech Ltd.
Trial code: NCT07440225
Record updated: 2 October 2026
Original description: Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).Read full original descriptionShow less
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).
Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.
The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
The main inclusion criteria include but are not limited to the following:; Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye); The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment; The main exclusion criteria include but are not limited to the following; Has uncontrolled blood pressure at screening; History of any prior macular laser photocoagulation in the study eye; History of uveitis in either eye; History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study; Has uncontrolled glaucoma in the study eye; Active retinal disease other than the condition under investigation in the study eye; Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye.
ClinicalTrials.gov NCT07440225